Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency
Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency is a paper indexed in PICO Portal from OpenAlex.
How many citations does Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency have?
Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency has 218 citations in the OpenAlex counts PICO Portal stores.
When was Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency published?
Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency has 2016 year in the PICO Portal index.
What is the open-access status of Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency?
Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency has bronze oa status in the PICO Portal index.
What is the DOI of Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency?
The DOI for Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency is on the source record.
What is the PMID of Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency?
The PMID for Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency is on the source record.
What is the OpenAlex record for Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency?
The OpenAlex for Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency is on the source record.